Stop missing out on important events!
After Macy’s Inc (NYSE:M) stock rallied in the wake of its stronger-than-expected first quarter results, multiple analysts were bearish on the shares, saying that Macy’s stock probably can’t advance much further going forward. For example, Citi’s Paul Lejuez wrote that Macy’s first quarter results were “as good as it gets” and kept a “Sell” rating on Macy’s stock.
SHLD PFH JCP KTP M ANF GPS SHLDW BBY
As the Pentagon struggles to recruit a more tech-savvy workforce, it's facing the confusion of many an old-timer: What to make of people who invest or trade in Bitcoin.
Rio Tinto Group is ready to accept a $US3.5 billion ($4.4 billion) deal with Indonesia for its interest in the giant Grasberg copper and gold mine, according to people with knowledge of the discussions.
RTPPF RIO RIO RIO RTNTF FCX
Latest Activist 13D and 13G Filings
Every investor that acquires 5% of a company is required to file a beneficial ownership filing, which is either a Form 13D or Form 13G, within ten (10) days of the event. If the investor intends to influence management, then they are considered an activist investor and must file a 13D. There is evidence that suggests investing alongside activist investors is a stock market investing strategy that can produce excess returns. This free screener shows all of the required Schedule 13D filings made by activist investors.
|2018‑05‑22||SC 13D/A||BELFB / Bel Fuse||GAMCO INVESTORS, INC. ET AL||281,652||12.95|
|2018‑05‑22||SC 13D/A||EQM / EQT Midstream Partners||EQT GP Holdings, LP||27,700,925||32.0|
|2018‑05‑22||SC 13D/A||DEPO / DepoMed||Starboard Value LP||2,703,995||4.3|
|2018‑05‑22||SC 13D/A||USNA / USANA Health Sciences||Wentz Myron W||11,025,753||45.8|
|2018‑05‑22||SC 13D||BNKL / Bionik Laboratories||E.c.i. Sa||15,729,099||6.3|
|2018‑05‑22||SC 13D/A||PFSW / PFSweb||Ancora Advisors, LLC||1,190,672||6.22|
|2018‑05‑22||SC 13D||EHIC / eHi Car Services||Burford Capital Investment Management Llc||4,900,394||6.6|
|2018‑05‑22||SC 13D||GDP / Goodrich Petroleum||Gen IV Investment Opportunities, LLC||1,838,510||15.9|
|2018‑05‑22||SC 13D/A||RMP / Rice Midstream Partners||Eqt Corp||28,757,246||28.1|
|2018‑05‑22||SC 13D/A||EQGP / EQT GP Holdings||EQT Gathering Holdings, LLC||276,008,766||91.3|
Latest Research Reports
Fintel Research Reports are free Wikipedia-style reports that are created and edited by people just like you. If you are an expert on a company and would like to help your fellow investors make more informed investing decisions, then you should become a Fintel Contributing Analyst. To do this, register on the site, message us in the online chat, and we will get you started.
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
Stock screens allow users to filter the companies listed on the stock market by various attributse, in order to screen out those that are undesirable. Stock screens on Fintel are made from a rich formula language that allows the utmost flexibility.
Financial Charts by Fintel.io
Top Institutional Investors
|Vanguard Group Inc|
|FMR LLC / Fidelity|
|BlackRock Fund Advisors|
|Capital World Investors|
|Capital Research Global Investors|
|Berkshire Hathaway Inc||Warren Buffett|
|Renaissance Technologies LLC||James Simons|
|Tiger Global Management Llc||Chase Coleman, Feroz Dewan|
|Third Point LLC||Dan Loeb|
|Baker Brothers Advisors LP||Julian and Felix Baker|
|Melvin Capital Management LP||Gabriel Plotkin|
|Baupost Group LLC/MA||Seth Klarman|
|ValueAct Holdings, L.P.||Jeff Ubben|
|Gotham Asset Management, LLC||Joel Greenblatt|
|Pershing Square Capital Management, L.P.||Bill Ackman|
|Starboard Value LP||Jeffrey Smith|
|GreenLight Capital Inc||David Einhorn|
|Hitchwood Capital Management LP||James Warby Crichton|
|Duquesne Family Office LLC||Stanley Druckenmiller|
|Sabby Management, LLC||Hal David Mintz|
|Bodenholm Capital AB|
|Pine River Capital Management L.P.||Brian Taylor and James Clark|
|Scion Asset Management, LLC||Dr. Michael Burry|